StarZero All shows Try the podcast clipper →

Humira

4 statements across 3 episodes · 1 bullish · 1 bearish · 3 people on the record · first statement Dec 11, 2023 by Julie Yoo · said 6 times in 3 episodes since 2023 · across every show →

Mentions by year

brought up most by Mark Cuban (2), Lada Nuzhna (2), Julie Yoo (2)

tap a year for its mentions
001121202320242025episodesmentions
011202320242025episodes it came up in
0010.521202320242025episodesmentions per episode
2025 2 mentions in 1 episode
2024 2 mentions in 1 episode
2023 2 mentions in 1 episode

every mention, scene by scene, with the transcript →

Everything said about Humira, oldest first

Dec 11, 2023
Assertion Supported
Yoo: Humira was history's best-selling US drug, treating 300,000 annually
“There's a drug called Humira, which was the best-selling drug ever in the history of American drug industry, and that drug was used by roughly 300,000 Americans each year”
Julie Yoo Dec 11, 2023 ▶ 6:00 Big Ideas in 2024: Democratizing “Miracle Drugs” with Julie Yoo
Mar 5, 2024 negative
Assertion Supported
Cuban: PBMs exclude $700 biosimilar Usimri to protect drug margin revenues
“Humira is about 8000 dollars a month. Six to 8000 dollars a month. USIMRI is about 700 dollars a month. But they won't add USIMRI to their formularies because they don't want to use the revenue in the margin.”
Mark Cuban Mar 5, 2024 ▶ 10:33 Sharks Never Stop Swimming: A Conversation with Mark Cuban
Nov 14, 2025
Insight
Nuzhna: Biotech companies should avoid being contrarian on novel biological mechanisms
“And I think biology is like one of the areas where you really don't want to be contrarian. You don't want to be the only company pursuing some obscure mechanism. Usually you want to have some literature validation, but in both of these cases, it was either a b…”
Lada Nuzhna Nov 14, 2025 ▶ 53:57 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation
Nov 14, 2025 positive
Assertion Partly supported
Nuzhna: Humira succeeded as the first human monoclonal antibody, not first-to-market
“Humira was also not the first TNF-alpha antibody out there. It was like third to market, third TNF-alpha antibody to be approved, but it was the first human monoclonal antibody, one of the first ones to be approved. And all the previous ones were antibodies fr…”
Lada Nuzhna Nov 14, 2025 ▶ 53:31 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 1,000 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.

Try the podcast clipper Learn more